Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy for glioblastoma, an aggressive form of brain cancer that is often difficult to treat. Their project is now entering the final preclinical stage of development, according to the university. The goal is to start clinical studies within four years. “Extremely few breakthroughs have been made around…
You must be logged in to read/download the full post.
The post Uppsala in Last Preclinical Stage for New CAR T-cell Product for Glioblastoma appeared first on BioNewsFeeds.